ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Novartis has licensed non-U.S. rights to Ophthotech’s wet age-related macular degeneration drug Fovista. In exchange for rights to develop and sell Fovista, Novartis will pay $200 million up front as well as a potential $830 million in milestones. The drug, an anti-platelet-derived growth factor aptamer, is now in Phase III clinical studies. Novartis intends to sell it as a stand-alone product and develop a combination with an antivascular endothelial growth factor agent.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter